AC Immune SA
ACIU
$2.19
$0.041.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 1.10M | 1.29M | 29.46M | 759.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 1.10M | 1.29M | 29.46M | 759.70K |
| Cost of Revenue | 20.40M | 17.70M | 17.97M | 16.74M | 18.95M |
| Gross Profit | -18.81M | -16.60M | -16.68M | 12.72M | -18.19M |
| SG&A Expenses | 4.72M | 4.94M | 4.54M | 4.34M | 5.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -33.90K | 1.10K | -15.90K | -22.00K | -45.30K |
| Total Operating Expenses | 25.09M | 22.65M | 22.50M | 21.06M | 23.94M |
| Operating Income | -23.50M | -21.55M | -21.20M | 8.40M | -23.18M |
| Income Before Tax | -25.69M | -21.17M | -17.99M | 6.36M | -25.17M |
| Income Tax Expenses | -- | -- | 3.40K | -- | -- |
| Earnings from Continuing Operations | -25.69M | -21.17M | -17.99M | 6.36M | -25.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.69M | -21.17M | -17.99M | 6.36M | -25.17M |
| EBIT | -23.50M | -21.55M | -21.20M | 8.40M | -23.18M |
| EBITDA | -23.06M | -21.15M | -20.79M | 8.82M | -22.76M |
| EPS Basic | -0.26 | -0.21 | -0.18 | 0.06 | -0.25 |
| Normalized Basic EPS | -0.16 | -0.13 | -0.11 | 0.04 | -0.16 |
| EPS Diluted | -0.26 | -0.21 | -0.18 | 0.06 | -0.25 |
| Normalized Diluted EPS | -0.16 | -0.13 | -0.11 | 0.04 | -0.16 |
| Average Basic Shares Outstanding | 100.63M | 100.41M | 99.99M | 99.84M | 99.55M |
| Average Diluted Shares Outstanding | 100.63M | 100.41M | 99.99M | 100.86M | 99.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |